Tolvaptan as a new generation of oral selective vasopressin receptor antagonist, has become the ideal drug for patients with cirrhosis refractory ascites in many countries such as Europe, Japan and China, and has been recommended by the United States Food and Drug Administration for hyponatremia treatment of high capacity, positive capacity.However, most of the experimental studies and clinical observations are limited to the assessment of short-term efficacy of tolvaptan, and can not adequately confirm the feasibility of its long-term use.In this review, we focus on the long-term efficacy and safety of oral tolvaptan in treatment of liver cirrhosis with refractory ascites by reviewing the recent literatures.